Updated:
NB Capital
Representative Investments by Florian Schönharting Role: Co-Founder Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of...
NB Capital
Representative Investments by Florian Schönharting Role: Co-Founder Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer and autoimmune diseases, based on proprietary next generation antibody technologies. Ticker: GEN.CO - Market cap:
General information
Firm type
Private Equity
Year founded
2001
AUM
Approximately $1B in discretionary capital (per firm website)
Location
Region
Europe
Country
Denmark
City
Copenhagen
Corporate office
Copenhagen, Denmark
Principals
Florian Schönharting
Chief Executive Officer
Sector focus
Frequently asked questions
Who runs investment decisions at NB Capital?
CEO Florian Schönharting leads investment decisions. He co-founded Genmab and has deployed capital across the biopharma sector for more than 25 years, from seed-stage company formation to activist campaigns in large-cap public drug developers.
How does NB Capital source proprietary deal flow?
The firm sources through Schönharting’s direct network as a serial biotech founder and board-level operator. By co-founding companies such as Genmab and Forward Pharma, the team accesses early-stage science and spin-out opportunities before they reach broad institutional auction processes.
Does NB Capital participate in fund commitments or only direct deals?
The firm makes direct public and private equity investments. It has acted as founder, co-founder, seed investor, pre-IPO backer and activist public investor. There is no public indication that it commits capital to third-party venture or buyout funds.
What investment stages does NB Capital typically target?
NB Capital invests across the full drug-development lifecycle, from seed and company formation through pre-IPO, public equity and activist campaigns. Its past deals include founding Forward Pharma, seed-investing in BioMarin, and running activist positions in Facet Biotech and Élan.
Where does the underlying capital come from?
NB Capital was seeded in 2001 by experienced biotech investors and a pharmaceutical company. Its current investor base is globally spread across institutional investors, sovereign wealth funds and family offices.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: